Lymph node metastasis (LNM) is correlated with decreased survival, indicating high tumor malignancy and being a potential source for subsequent fatal metastases. Targeted therapies inhibiting the formation of LNM, while eliminating established metastatic foci, could provide synergistic effects by reducing the incidence and growth of metastasis. Based on the inhibitory activity of cRGD peptide against the development of metastasis, and the LNM targeting ability of systemically injected drug-loaded polymeric micelles, herein, we studied the capability of cRGD-installed polymeric micelles incorporating the platinum anticancer drug (1,2-diaminocylohexane)platinum(II) (DACHPt) for cooperatively inhibiting the formation and progression of LNM. As cRGD-installed DACHPt-loaded micelles (cRGD-DACHPt/m) presented similar size, drug loading and surface charge to non-conjugated micelles (MeO-DACHPt/m), the differences in the biological performance of the micelles were endorsed to the effect of the ligand.
Introduction
Cancer metastasis is one of the most threatening aspects in cancer, representing more than 90% of cancer-related deaths [1] . Particularly, metastasis to regional lymph nodes is clinically significant, as it is the first site of metastasis in several types of cancer, including melanoma, breast, gastric, colon, prostate, and head and neck cancer, being associated with poor prognosis [2] [3] [4] [5] [6] .
Besides indicating a more malignant tumor biology, lymph node metastasis (LNM) are also the source for subsequent fatal metastases. Indeed, recent pre-clinical and clinical studies have shown that tumor cells spread more to systemic sites from LNM than from primary tumors, probably supported by the microenvironment of lymph nodes [7] [8] [9] [10] . Therefore, therapeutic approaches capable of effectively eradicating LNM could have a radical impact on the care of cancer by decreasing the incidence of metastases to distant organs and improving overall survival.
Several therapeutic strategies have been considered for treating LNM, including the inhibition of LNM development or the elimination of already developed LNM. Accordingly, lymphangiogenesis inhibitors have been widely studied for reducing the formation of LNM through the decreased connection of primary tumors with lymph nodes, showing less distant metastases and extended survival in various tumor models [11] , though their efficacy is limited against established tumors [12] [13] [14] . On the other hand, LNM are currently treated by radiotherapy [15] [16] [17] , or by intralymphatic, or locally [18] or systemically administered chemotherapy [19] [20] [21] [22] , which present serious issues regarding toxicity, efficacy and residual disease, jeopardizing survival and QOL of patients [23] . Thus, targeted therapies that can simultaneously inhibit the formation of LNM and treat both primary tumors and LNM, regardless of their anatomical position, could synergistically increase their effectiveness and dramatically improve therapeutic outcomes.
Nanomedicines have the potential for achieving such synchronized targeted therapies by including inhibitory and cytotoxic functions in their architecture. Nanomedicines, such as liposomes [24.25] , polymer-drug conjugates [26, 27] , self-assembled polymeric nanostructures [28, 29] , nanoparticles [30] [31] [32] , and dendrimers [33, 34] ,have demonstrated capability for improving efficacy and reducing side effects. Among them, polymeric micelles having a drug-loaded hydrophobic core surrounded by a poly(ethylene glycol) (PEG) hydrophilic shell have shown outstanding features for selectively delivering drugs to solid tumors, including their relatively small size, high drug loading capacity and prolonged blood circulation [29] , and several micelle formulations incorporating anticancer drugs are showing improved survival and reduced side effects in various clinical trials [35] . By using polymeric micelles conjugating the parent compound of the anticancer drug oxaliplatin, i.e. (1,2-diaminocyclohexane)platinum(II) (DACHPt), via polymer-metal complex formation with poly(ethylene glycol)-b-poly(L-glutamic acid) (PEG-b-P(Glu)) copolymer [36, 37] ( Figure 1A) , we have recently demonstrated that it is also possible to target and treat LNM through systemic administration of micelles [36, 37] . Thus, herein, we evaluated the cooperative effect of including a metastasis inhibitory function to the cytotoxic capability of DACHPt-loaded micelles (DACHPt/m) through the conjugation of cyclic Arg-Gly-Asp (cRGD) peptides on the micelles' surface ( Figure 1B) , since cRGD peptide has shown to reduce the development of metastasis by inhibiting angiogenesis or integrin-dependent metastatic processes [38] [39] [40] . cRGD peptide has been used to improve the targeting of nanomedicines by selectively binding to α v β 3 /α v β 5 integrins overexpressed on cancer cells and neovasculature [41] [42] [43] , and our previous report revealed that cRGD-installed DACHPt/m (cRGD-DACHPt/m) enhanced drug delivery efficiency in a glioblastoma tumor model overexpressing α v β 3 /α v β 5 integrins [44] . In current study, the in vivo inhibitory and antitumor activities of cRGD-DACHPt/m were assessed in a syngeneic melanoma model, which allow us to construct a model having only metastases by directly resecting the primary tumor in the footpad of mice, and compared to that of non-conjugated micelles (MeO-DACHPt/m) to elucidate the conditions for their efficacy enhancement. 
Materials and Methods

Materials
Dimethyl sulfoxide (>99%), triethylamine (TEA, >99%) and methanesulfonyl chloride (MsCl, >99%) were purchased from Wako Pure Chemical Industries, Ltd., (Tokyo, Japan) and used after distillation over CaH 2 . α-Methoxy-ω-amino poly(ethylene glycol) (MeO-PEG-NH 2 , 12,000 g/mol, NOF Corporation, Tokyo, Japan) was purified through an ion exchange CM Sephadex C-50 
Cells and Animals
B16F10-luc murine melanoma cell line was purchased from Xenogen (Alameda, CA).
B16F10-GFP cells were purchased from Anticancer, Co. (San Diego, CA). Human Umbilical Vein Endothelial cells (HUVEC) were bought from Lonza (Tokyo, Japan). C57BL6/J mice were purchased from Oriental Yeast Co., Ltd. (Tokyo, Japan). All animal experiments were done under the ethical guidelines of The University of Tokyo. [Mal-PEG-b-P(Glu)] (molecular weight of PEG: 12,000; degree of polymerization of glutamic acid:
Synthesis of Block Copolymers
Methoxy
40) was synthesized as previously reported [44] . In brief, NaN 3 was added to THP-PEG-Ms to obtain N 3 -PEG-THP. N 3 -PEG-THP in methanol was mixed with aq. HCl to obtain N 3 -PEG-OH.
MsCl solution in THF was added to the mixture of TEA and N 3 -PEG-OH to prepare N 3 -PEG-Ms.
N 3 -PEG-NH 2 was formed by dissolving N 3 -PEG-Ms in 25% ammonia. Then, N 3 -PEG-NH 2 was used as an initiator of the ring opening polymerization of BLG-NCA similarly to
MeO-PEG-b-P(Glu) to obtain N 3 -PEG-b-PBLG. N 3 -PEG-b-PBLG was deprotected with 0.5 N NaOH at room temperature to obtain N 3 -PEG-b-P(Glu). Then, N 3 -PEG-b-P(Glu) was reacted with PdNPs, followed by sulfo-GMBS to synthesize Mal-PEG-b-P(Glu). To prepare fluorescent labeled
MeO-PEG-b-P(Glu) or Mal-PEG-b-P(Glu), polymers and Alexa 555-NHS or Alexa 647-NHS were mixed in DMSO for 3 h (1:1 molar eq.). Then, the polymers were dialyzed against water and further purified by using prepacked PD MidiTrap G-10 gravity columns (GE Healthcare Life Sciences; Pittsburgh, USA). Resulting 10% mol/mol of the copolymers were fluorescently labeled.
Preparation of DACHPt-loaded Micelles (MeO-DACHPt/m)
MeO-DACHPt/m were prepared with MeO-PEG-b-P(Glu) as previously described [45] . 
Preparation of cRGD-installed DACHPt-loaded Micelles (cRGD-DACHPt/m)
cRGD-DACHPt/m were prepared as previously described [44] . MeO-PEG-b-P(Glu) and
Mal-PEG-b-P(Glu) copolymers ( determine the onset of the metastatic disease. Twenty four-hours after the metastasis in lymph node was detected, the administration of drugs was initiated. This procedure allowed us to minimize the variability of the bioluminescent signal from the metastasis. Moreover, the studies were performed in 2 models, the model "with-primary-tumor", i.e. both primary tumor and metastasis were present during the evaluation of the drugs, and the model "without-primary-tumor", that is, the mice had their primary tumor on their footpad resected after the detection of their lymph node metastases.
The evaluation of the drugs in the latter group was done 24 h after the surgery.
In Vivo Antitumor Activity
Mice (n = 5) with-and without-primary-tumor models were injected 3-times with PBS, 
where a and b represent the long and short axis of the tumor, respectively. The photon radiance from the lymph node metastases (of both tumor models) was measured every 2 days by IVIS 10 min after intraperitoneal injection of luciferin (150 mg/kg). The bioluminescent signal in the lymph nodes was quantified and taken as a parameter of the tumor burden. In addition, the body weight of mice was followed during the experiment to determine the toxicity of the drugs.
Metastasis Inhibition
Four-days after inoculation with B16F10-luc cells, mice of the model "with-primary-tumor" were injected intraperitoneally with luciferin (150 mg/kg) and imaged for 5 min by IVIS to confirm they still have not developed metastasis. Then, the mice were divided in 3 groups and the experiment was started, with the mice receiving 3 intravenous injections of PBS, MeO-DACHPt/m (2 mg/kg on a DACHPt basis), cRGD-DACHPt/m (2 mg/kg on a DACHPt basis)
and MeO-DACHPt/m (2 mg/kg on a DACHPt basis) mixed with free cRGD peptide (37 μg/kg, which is similar to the amount conjugated on cRGD-DACHPt/m) on days 0, 2 and 4. Then, bioluminescent imaging with 5 min exposure was repeated every 2 days to examine the incidence of LNM. The statistical significance was determined by Fisher's exact test.
Drug Accumulation in Metastatic Lymph Nodes
Drug accumulation was evaluated by using the models "with-primary-tumor" and "without-primary-tumor" (n = 8 for micelles and n = 4 for oxaliplatin). MeO-DACHPt/m (5 mg/kg on a DACHPt basis), cRGD-DACHPt/m (5 mg/kg on a DACHPt basis), or the free platinum drug, oxaliplatin (5mg/kg) were injected intravenously, and the metastatic lymph nodes were harvested 24 h after the injection. Then, the tissues were digested in hot 90% nitric acid, and the solutions were evaporated to dryness. The Pt amount in the metastatic lymph nodes was then measured by ICP-MS, after reconstituting the solution with 1% nitric acid. The significance of the results was determined by Student's t-test.
Intravital confocal laser scanning microscopy of metastatic lymph nodes
The intravital confocal laser scanning microscopy was done as previously reported [27] .
The B16F10-GFP metastatic brachial lymph node was surgically exposed 48 h after resection of primary tumor, and then the lymph node was fixed by using a vacuum system [46] . Alexa 555-labeled MeO-DACHPt/m and Alexa 647-labeled cRGD-DACHPt/m at a dose of 10 mg/kg on a DACHPt basis were co-injected into the tail vein. A Nikon A1R confocal laser scanning microscope system with ECLIPSE FN1 (Nikon, Japan) was used to acquire all in vivo pictures. Alexa 555-labeled MeO-DACHPt/m and Alexa 647-labeled cRGD-DACHPt/m were detected by using 560/620 nm excitation/emission filters and 633/670 excitation/emission filters, respectively.
Isolation of Tumor Cells from Lymph Node Metastases
The metastatic lymph nodes were harvested 10 days after the tumor cell inoculation. The tissues were minced with a cell strainer processed in 1x trypsin-EDTA solution for 30 min in 37 ˚C, and filtered. The cell suspension was then added in the RPMI 1640 with 10% FBS, and incubated in 37 ˚C until the cells reached confluent. This process was repeated 2 more times to prepare B16F10-luc-LN3 cells.
In vitro Cytotoxicity Assay
B16F10-luc, B16F10-luc-LN3 cells cultured in 96-well multiplates with RPMI 1640 medium containing 10% FBS, while HUVEC were plated on collagen I-coated 96-well multiplates and supplemented with EBM™-2 BulletKit™ medium (100 µL, 5 x 10 3 cells). Twenty-four hours later, serially diluted MeO-DACHPt/m or cRGD-DACHPt/m were added into the wells (100 µL/well), and 6 h later the media containing the micelle solutions were removed. Then, fresh medium was added and the cells were cultured for another 48 h. Finally, the cell viability was evaluated by using Cell Counting Kit-8 (Dojindo, Tokyo, Japan). A similar experiment was performed on B16F10-luc or B16F10-luc-LN3 cells cultured on 96-well Cell-able Oncology™ plates (100 µL, 1 x 10 3 cells) for 48 h to assemble multicellular spheroids. The spheroids were exposed to serially diluted MeO-DACHPt/m or cRGD-DACHPt/m for 6 h, and then washed with fresh media. The cell viability of the spheroids was determined by bioluminescent imaging by IVIS after addition of 100 μL of luciferin (15 mg/mL).
In Vitro Wound Healing Assay
The MeO-DACHPt/m (6 µM of a DACHPt basis) with free cRGD peptide (0.05 µg/mL, which is similar to that conjugated on the micelles), free cRGD peptide (0.05 µg/mL), and PBS. Then, the pictures of the scratches were taken again after 10 h of incubation. The distance of cell migration was measured by comparing these initial pictures and 10 h pictures by using ImageJ. In addition, the effect of the concentration of free cRGD peptide of the cell migration was studied using the same method. The statistical significance was determined by using Student's t-test.
In Vitro Cytoselect™ Cell Migration Assay
This experiment was performed by using Cytoselect™ 96-well cell migration assay (8 µm) (Cell Biolabs; San Diego, CA). RPMI-1640 medium containing 10% FBS was added into the wells of the feeder tray, followed by placing the membrane chamber into the feeder tray. were detached by Cell Detachment Solution provided in the kit and the cell number was evaluated by IVIS after adding 100 μL luciferin (15 mg/mL). The statistical significance was determined by using Student's t-test.
Results and Discussion
In Vivo Antitumor Activity and Metastasis Inhibition
MeO-DACHPt/m and Mal-DACHPt/m were prepared by mixing DACHPt with
MeO-PEG-b-P(Glu) and MeO-PEG-b-P(Glu)/Mal-PEG-b-P(Glu) (mixture in 3:1 molar ratio),
respectively. To prepare cRGD-DACHPt/m, we then conjugated cRGD peptide on 20% of the PEG chains of Mal-DACHPt/m, as this degree of conjugation can provide cRGD-installed micelles with sufficient targeting ability for α v β 3 /α v β 5 integrins [44] and still achieve an extended blood circulation comparable to that of MeO-DACHPt/m [44, 45] . The size distribution, the drug loading and the zeta-potential of the micelles were determined and presented in Table 1 . Both
MeO-DACHPt/m and cRGD-DACHPt/m showed comparable size, drug incorporation and surface charge, which allow us to attribute their differences in activity to the ligand installation. Table 3 ). The cytotoxicity of both micelles against HUVEC was comparable and lower than that of micelles against B16F10-luc and B16F10-luc-LN3, suggesting that the in vivo activity of these micelles is mainly toward cancer cells rather than vascular endothelial cells of tumors (Table 3) . Thus, the analogous cytotoxicity of MeO-DACHPt/m and cRGD-DACHPt/m observed for the more metastatic sub-line, B16F10-luc-LN3, cannot explain the improved inhibition of metastasis formation and efficacy against LNM of cRGD-DACHPt/m, thereby, we proceeded to test our second and third hypotheses. 
In Vivo Antitumor Activity against LNM after Tumor Resection
To study the second proposed mechanism for the enhanced metastasis inhibition of cRGD-DACHPt/m, the in vivo antitumor activity of the micelles was evaluated against developed metastasis in the lymph nodes after resection of the primary tumor, which allows us to discriminate the antitumor effect of the micelles against the metastastic foci. To prepare the animal model, B16F10-luc cells were injected in the footpad of C57BL6/J mice, the tumors were allowed to grow, and the presence of the lymph node metastases was confirmed after 1-min exposure in IVIS. Then, the primary tumors were resected, and the evaluation of the antitumor activity of intravenously 
